Weighted average YTM declined from 16.9% to 15.8%.
Net income fell 52% year-over-year due to increased credit loss provisions.
DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.
Maintained quarterly dividend of $0.47 despite falling operating cash flow.
The Q1 2026 filing presents a company in a delicate transition, balancing high-yield returns against escalating credit risks. While REFI has successfully maintained its dividend and reported positive net income, the divergence between GAAP net income and operating cash flow suggests a reliance on non-cash accruals and revolving credit draws to sustain distributions. The restoration of the $29 million 'Judgment Loan' to accrual status is a positive sign, but the emergence of new non-accrual loans indicates that credit volatility remains a constant feature of the cannabis-finance niche. Ultimately, the investment case for REFI now hinges on the speed and scope of federal rescheduling. If the DEA's move toward Schedule III translates into tangible liquidity for borrowers, REFI could see a broad-based improvement in credit quality. However, until that catalyst materializes, investors must weigh the attractive current yield against a backdrop of increasing loan loss provisions and a concentrated portfolio that leaves little room for underwriting error.